The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study

Fluticasone Propionate ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Double Blind ◽

Parallel Group Study ◽

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

10.1016/s2213-2600(12)70052-8 ◽

2013 ◽

Vol 1 (1) ◽

pp. 51-60 ◽

Cited By ~ 173

Author(s):

Claus F Vogelmeier ◽

Eric D Bateman ◽

John Pallante ◽

Vijay KT Alagappan ◽

Peter D'Andrea ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Parallel Group Study ◽

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

10.1016/s2213-2600(13)70052-3 ◽

2013 ◽

Vol 1 (3) ◽

pp. 199-209 ◽

Cited By ~ 284

Author(s):

Jadwiga A Wedzicha ◽

Marc Decramer ◽

Joachim H Ficker ◽

Dennis E Niewoehner ◽

Thomas Sandström ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Double Blind ◽

Parallel Group Study ◽

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.201901-0048le ◽

2019 ◽

Vol 200 (5) ◽

pp. 642-645 ◽

Cited By ~ 1

Author(s):

Jaclyn A. Smith ◽

Lorcan McGarvey ◽

Alyn H. Morice ◽

Surinder S. Birring ◽

Jadwiga A. Wedzicha ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group Study ◽

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Respiratory Research ◽

10.1186/s12931-017-0647-1 ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 16

Author(s):

Krishna K. Pudi ◽

Chris N. Barnes ◽

Edmund J. Moran ◽

Brett Haumann ◽

Edward Kerwin

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group Study ◽

A randomised open label parallel group study on evaluation of efficacy and safety of gemifloxacin versus cefpodoxime in chronic obstructive pulmonary disease patients.

International Journal of Pharma and Bio Sciences ◽

10.22376/ijpbs.2017.8.2.p324-331 ◽

2017 ◽

Vol 8 (2) ◽

Author(s):

RENU KA ◽

VASANTHI C ◽

DARLING CHELLATHAI

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Open Label ◽

Parallel Group Study ◽

Faculty Opinions recommendation of Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718348198.793494105 ◽

2014 ◽

Author(s):

Adam Wanner ◽

Timothy Scialla

Keyword(s):

Pulmonary Disease ◽

Controlled Trial ◽

Chronic Obstructive ◽

Double Blind ◽

Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial

10.1016/s2213-2600(13)70200-5 ◽

2014 ◽

Vol 2 (1) ◽

pp. 63-72 ◽

Cited By ~ 51

Author(s):

Henrik Watz ◽

Helen Barnacle ◽

Benjamin F Hartley ◽

Robert Chan

Keyword(s):

Pulmonary Disease ◽

Controlled Trial ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

P38 Mapk Inhibitor ◽

Mapk Inhibitor

A Comparison of Tiotropium 18µg, Once Daily and Ipratropium 40µg, 4 Times Daily in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults with Chronic Obstructive Pulmonary Disease

Tuberculosis and Respiratory Diseases ◽

10.4046/trd.2005.58.5.498 ◽

2005 ◽

Vol 58 (5) ◽

pp. 498 ◽

Cited By ~ 4

Author(s):

Seung Joon Kim ◽

Myung Sook Kim ◽

Sang Haak Lee ◽

Young Kyoon Kim ◽

Hwa Sik Moon ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Safety Study ◽

Double Blind ◽

Once Daily

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

10.1016/s2213-2600(13)70158-9 ◽

2013 ◽

Vol 1 (7) ◽

pp. 524-533 ◽

Cited By ~ 122

Author(s):

Marc L Decramer ◽

Kenneth R Chapman ◽

Ronald Dahl ◽

Peter Frith ◽

Gilles Devouassoux ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Once Daily ◽

Parallel Group Study ◽

The Design of and Rationale for the Effect of Perioperative Inhaled Tiotropium for Patients with Chronic Obstructive Pulmonary Disease in Esophageal Cancer Surgery (EPITOPE): an Open-Label, Randomized, Parallel-Group Study

European Surgical Research ◽

10.1159/000506512 ◽

2020 ◽

pp. 1-7

Author(s):

Akihiko Okamura ◽

Masayuki Watanabe ◽

Satoru Kitazono ◽

Haruka Manoshiro ◽

Emi Kasama ◽

...

Keyword(s):

Esophageal Cancer ◽

Pulmonary Disease ◽

Cancer Surgery ◽

Chronic Obstructive ◽

Open Label ◽

Parallel Group Study ◽

Esophageal Cancer Surgery ◽